Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

0.5677 +0.0476 (+9.15%)
Streaming Delayed Price Updated: 3:40 PM EDT, Aug 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,516,591
Open 0.5334
Bid (Size) 0.5621 (2)
Ask (Size) 0.5677 (2)
Prev. Close 0.5201
Today's Range 0.5170 - 0.5978
52wk Range 0.3546 - 2.740
Shares Outstanding 109,755,624
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
From Invivyd
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga

Performance

YTD
+18.3%
+18.3%
1 Month
-27.7%
-27.7%
3 Month
-36.9%
-36.9%
6 Month
-54.2%
-54.2%
1 Year
-56.0%
-56.0%

More News

Read More
These stocks that are showing activity before the opening bell on Thursday.
Via Chartmill
Demystifying Invivyd: Insights From 5 Analyst Reviews
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants
From Invivyd
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
Via Chartmill
Invivyd Announces Proposed Public Offering of Common Stock
From Invivyd
Via GlobeNewswire
Retail Chatter Surges Around Invivyd After Data Show Pemgarda Neutralizes XFG COVID-19 Variant
Via Stocktwits
Curious about the stocks that are showing activity after the closing bell on Monday?
Via Chartmill
Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)
From Invivyd
Via GlobeNewswire
Invivyd Revenue Jumps 413 Percent in Q2
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19
From Invivyd
Via GlobeNewswire
Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome
From Invivyd
Via GlobeNewswire
National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population
From Invivyd
Via GlobeNewswire
Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome
From Invivyd
Via GlobeNewswire
Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection
From Invivyd
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2
From Invivyd
Via GlobeNewswire
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
From Invivyd
Via GlobeNewswire
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19
From Invivyd
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga

Frequently Asked Questions

Is Invivyd, Inc. - Common Stock publicly traded?
Yes, Invivyd, Inc. - Common Stock is publicly traded.
What exchange does Invivyd, Inc. - Common Stock trade on?
Invivyd, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Invivyd, Inc. - Common Stock?
The ticker symbol for Invivyd, Inc. - Common Stock is IVVD on the Nasdaq Stock Market
What is the current price of Invivyd, Inc. - Common Stock?
The current price of Invivyd, Inc. - Common Stock is 0.5677
When was Invivyd, Inc. - Common Stock last traded?
The last trade of Invivyd, Inc. - Common Stock was at 08/25/25 03:40 PM ET
What is the market capitalization of Invivyd, Inc. - Common Stock?
The market capitalization of Invivyd, Inc. - Common Stock is 62.31M
How many shares of Invivyd, Inc. - Common Stock are outstanding?
Invivyd, Inc. - Common Stock has 62M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.